Afficher la notice abrégée

Prevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation: Rationale and Design for PRESTIGE-AF Trial

dc.rights.licenseopenen_US
dc.contributor.authorKOROMPOKI, Eleni
dc.contributor.authorHEUSCHMANN, Peter
dc.contributor.authorHARVEY, Kirsten H
dc.contributor.authorFIESSLER, Cornelia
dc.contributor.authorMALZAHN, Uwe
dc.contributor.authorHÜGEN, Klemens
dc.contributor.authorULLMANN, Sabine
dc.contributor.authorTODD, Gabriele Putz
dc.contributor.authorSCHUHMANN, Carolin
dc.contributor.authorMONTANER, Joan
dc.contributor.authorSIBON, Igor
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDEBETTE, Stephanie
dc.contributor.authorENZINGER, Christian
dc.contributor.authorROPELE, Stefan
dc.contributor.authorRÜCKER, Viktoria
dc.contributor.authorHAAS, Kirsten
dc.contributor.authorHARVEY, Emily
dc.contributor.authorWOLFE, Charles
dc.contributor.authorWANG, Yanzhong
dc.contributor.authorNIELSEN, Peter B
dc.contributor.authorCASO, Valeria
dc.contributor.authorLIP, Gregory Y H
dc.contributor.authorLANE, Deirdre A
dc.contributor.authorHALSE, Omid
dc.contributor.authorRINGLEB, Peter
dc.contributor.authorHAEFELI, Walter E
dc.contributor.authorFOERSTER, Kathrin I
dc.contributor.authorWURMBACH, Viktoria S
dc.contributor.authorVELTKAMP, Roland
dc.date.accessioned2025-01-28T11:10:03Z
dc.date.available2025-01-28T11:10:03Z
dc.date.issued2024-12-31
dc.identifier.issn2567-689Xen_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/204621
dc.description.abstractEnAdequate secondary prevention in survivors of intracerebral hemorrhage (ICH) who also have atrial fibrillation (AF) is a long-standing clinical dilemma because these patients are at increased risk of recurrent ICH as well as of ischemic stroke. The efficacy and safety of oral anticoagulation, the standard preventive medication for ischemic stroke patients with AF, in ICH patients with AF are uncertain. PRESTIGE-AF is an international, phase 3b, multi-center, randomized, open, blinded end-point assessment (PROBE) clinical trial that compared the efficacy and safety of direct oral anticoagulants (DOACs) with no DOAC (either no antithrombotic treatment or any antiplatelet drug). Randomization occurred in a 1:1 ratio and stratification was based on ICH location and sex. The two co-primary binary endpoints included ischemic stroke and recurrent ICH which will be analyzed hierarchically according to the intention-to-treat principle. Secondary efficacy endpoints encompassed all-stroke and systemic embolism, all-cause and cardiovascular mortality, major adverse cardiac events, and net clinical benefit. Secondary safety endpoints included any major hemorrhage and intracranial hemorrhage. All outcome events were adjudicated by an independent committee. Results of PRESTIGE-AF are expected to support risk-adjusted secondary prevention in ICH survivors with AF and to inform clinical guideline recommendations.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enIntracerebral Hemorrhage
dc.subject.enAtrial Fibrillation
dc.subject.enIschemic Stroke
dc.subject.enRandomized Controlled Trial
dc.subject.enDirect Oral Anticoagulants
dc.title.enPrevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation: Rationale and Design for PRESTIGE-AF Trial
dc.title.alternativeThromb Haemosten_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1055/a-2496-5492en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39740761en_US
bordeaux.journalThrombosis and Haemostasisen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamELEANOR_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDImperial College Londonen_US
bordeaux.identifier.funderIDHorizon 2020en_US
bordeaux.import.sourcepubmed
hal.identifierhal-04916472
hal.version1
hal.date.transferred2025-01-28T11:10:07Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Thrombosis%20and%20Haemostasis&rft.date=2024-12-31&rft.eissn=2567-689X&rft.issn=2567-689X&rft.au=KOROMPOKI,%20Eleni&HEUSCHMANN,%20Peter&HARVEY,%20Kirsten%20H&FIESSLER,%20Cornelia&MALZAHN,%20Uwe&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_ThrombHaemost_2024_Korompo ...
Taille:
383.2Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée